Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

EAST HANOVER, N.J., Nov. 7, 2011 /PRNewswire/ -- Novartis announced today new pivotal Phase III data showing 45% of children with active systemic juvenile idiopathic arthritis (SJIA) were able to substantially reduce their use of oral corticosteroids (often described as steroids) within 28 weeks of commencing treatment with ACZ885 (canakinumab) (p<0.0001)[1].

The results of the study, which met both primary endpoints, will be presented on November 9th at the American College of Rheumatology's (ACR) Annual Scientific Meeting in Chicago, US[1].

"The treatment of SJIA is a challenge given our current treatment options. Despite our best efforts, optimal disease control is often times elusive. We still must use steroids in the treatment of these children with SJIA. Steroids help manage many SJIA symptoms, such as fever and inflammation, but doctors try to minimize their use because of the potential negative impact on bones and growth," said Daniel Lovell, M.D., one of the study investigators and Professor of Pediatrics at the Cincinnati Children's Hospital Medical Center. "These data are exciting because they show that patients on ACZ885 were able to reduce their steroid use, and also experienced excellent disease control."

In addition, patients with SJIA on ACZ885 were nearly three times (0.37 hazard ratio) less likely to suffer a new flare. Therefore, only 27% of ACZ885-treated patients experienced a new flare, vs. 75% of patients on placebo during the study (p=0.0043)[1].

Data from this trial supports the safety and efficacy profile of ACZ885 in the study population. These results, along with data from a second pivotal study, are planned to form the basis for worldwide regulatory submissions in 2012. Side effects observed in this study were similar to those already seen for ACZ885's approved indication, including infections and neutropenia[1]. In addition, cases of macrophage activation syndrome (MAS) were reported in this study[1]
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 26, 2015 /PRNewswire/ - Fluorinov Pharma ... of Luke M. Beshar to its Board ... financial and pharmaceutical industry expertise as Fluorinov accelerates its ... the Fluorinov team, it is a pleasure to welcome ... a significant impact on the strategy, financial strength and ...
(Date:5/26/2015)... Boston, MA (PRWEB) May 26, 2015 ... that addresses a long-standing unmet biomedical need does not ... to a problem that has seen many prior failures ... to gaining acceptance and use is an irony that ... As a small, new start-up company, Asymmetrex ...
(Date:5/25/2015)... 2015 Phenome Networks, a software-as-a-service ... the availability, beginning May 31st, of its next-generation Phenome ... One solidifies Phenome Networks’ lead in the plant breeding ... and intuitive breeding workflow based on years of experience ... field design, and more. The new version of Phenome ...
(Date:5/22/2015)... 2015 Knowledgent , the data ... explores the potential of big data analytics in the ... developed to help life sciences and healthcare organizations understand ... gain critical business insights. , The life sciences and ... driven by patient profiling, compliance and regulatory requirements, and ...
Breaking Biology Technology:Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3Phenome Networks Announces its Next Generation Plant Breeding Management and Analytics Software 2Phenome Networks Announces its Next Generation Plant Breeding Management and Analytics Software 3New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2
... , INDIANAPOLIS and PERTH, Australia, July 16 Dow ... (NYSE: DOW ), and NemGenix, a Perth based biotechnology ... technologies to produce nematode-resistant crops. , , ... at NemGenix,s facilities in Perth. Financial terms of the agreement were ...
... , , NEW YORK, July ... is pioneering the pre-disease collection, processing and long-term storage of adult ... into an advisory consulting agreement with Dr. Cai Jianqian, (Mrs ... assist the company with its expansion into China and facilitate collaborations ...
... , RESEARCH TRIANGLE PARK, N.C., July 16 Chimerix, ... that Kenneth I. Moch has joined the company as Chief Operating ... brings more than 25 years of experience in managing and financing ... life science companies. In this newly-created position, Mr. Moch will ...
Cached Biology Technology:Dow AgroSciences, NemGenix Establish New Collaboration in Plant Biotechnology 2NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board 2NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board 3Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer 2
(Date:5/21/2015)... The Sync Project™ , a global ... today announced a collaborative partnership with Berklee,s Institute ... on collaboration on original research, joint course development and ... collaboration, The Sync Project and BerkleeICE are exploring the ... the 2015-2016 academic year.  The course ...
(Date:5/19/2015)... May 19, 2015  Technology is rapidly advancing, outpacing ... in the cloud. Passwords and their management are soon ... and standards-based specifications such as those developed by the ... of passwords presents for BYOD, COPE, IoT, and mobile ... identity protocol. In response to the ...
(Date:5/14/2015)... NEW YORK , May 14, 2015 ... specializing in identity verification and online remote ... Instructure, a software-as-a-service (SaaS) company and creator ... Shared customers of the two companies will ... Proctortrack in Canvas. As a ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... of the Walter and Eliza Hall Institute of Medical ... of the 2009 Pearl Meister Greengard Prize. ... the accomplishments of outstanding female scientists, at The Rockefeller ... prize was founded by Rockefeller Nobel laureate Paul Greengard ...
... highlands split and the Great Rift Valley formed, the ... different atmospheric circulation patterns than it does today, according ... central African nation. Neil J. Tabor, associate professor ... and an expert in sedimentology and isotope geochemistry, calculated ...
... over could benefit from new software* created at the National ... scientists has found a way to improve the efficiency of ... Alabama at Birmingham (UAB). Pneumonia is the world,s leading ... and poses a serious risk to elderly adults. The leading ...
Cached Biology News:Professor Suzanne Cory awarded 2009 Pearl Meister Greengard Prize 2Ethiopia's climate 27 million years ago had higher rainfall, warmer soil 2Scientists create NICE solution to pneumonia vaccine testing problems 2
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
PFM8 Antibody...
Rabbit polyclonal to NCoR2, prediluted ( Abpromise for all tested applications). entrezGeneID: 9612 SwissProtID: Q9Y618...
Goat anti-PITPN Class: Antibody Product Group: Miscellaneous Antibody...
Biology Products: